Efficacy and safety in adequate regimen of aflibercept therapy for patients with diabetic macular edema
Not Applicable
Recruiting
- Conditions
- diabetic macular edema
- Registration Number
- JPRN-UMIN000020787
- Lead Sponsor
- Shiga University of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Anti-VEGF therapy within the prior 3 months. Retinal photocoagulation within the prior 3 months. Steroid therapy within the prior 3 months. Major ocular surgery within the prior 3 months. A myocardial infarction or other cardiac event requiring hospitalization. Cerebrovascular accident, transient ischemic attack, or acute congestive heart failure.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways does aflibercept target in diabetic macular edema treatment?
How does aflibercept regimen efficacy compare to ranibizumab in Japanese DME patients?
Which biomarkers correlate with aflibercept response in JPRN-UMIN000020787 DME trial?
What are the most common adverse events reported in aflibercept DME trials in Asia?
How do aflibercept dosing strategies differ from bevacizumab in managing persistent DME?